About E3 ubiquitin-protein ligase RNF113A
E3 ubiquitin-protein ligase RNF113A (RNF113A) is a protein
from Homo sapiens identified by UniProt accession
O15541, 343 residues long.
MolForge cross-references it against 0 known binders and
18 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein ligase RNF113A |
|---|
| UniProt accession | O15541 |
|---|
| Gene | RNF113A |
|---|
| Organism | Homo sapiens |
|---|
| Length | 343 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (18)
Diseases linked to this target (Open Targets).
- trichothiodystrophy · score 0.66
- neurodegenerative disease · score 0.43
- cervical rib syndrome · score 0.06
- small cell lung carcinoma · score 0.06
- acute myeloid leukemia · score 0.04
- esophageal squamous cell carcinoma · score 0.02
- calf circumference measurement · score 0.02
- systemic juvenile idiopathic arthritis · score 0.02
- neoplasm · score 0.02
- cancer · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O15541-F1 | alphafold | PREDICTED | 68.65 | — |
Amino-acid sequence (343 residues)
MAEQLSPGKA VDQVCTFLFK KPGRKGAAGR RKRPACDPEP GESGSSSDEG CTVVRPEKKR VTHNPMIQKT RDSGKQKAAY GDLSSEEEEE NEPESLGVVY KSTRSAKPVG PEDMGATAVY ELDTEKERDA QAIFERSQKI QEELRGKEDD KIYRGINNYQ KYMKPKDTSM GNASSGMVRK GPIRAPEHLR ATVRWDYQPD ICKDYKETGF CGFGDSCKFL HDRSDYKHGW QIERELDEGR YGVYEDENYE VGSDDEEIPF KCFICRQSFQ NPVVTKCRHY FCESCALQHF RTTPRCYVCD QQTNGVFNPA KELIAKLEKH RATGEGGASD LPEDPDEDAI PIT
Explore E3 ubiquitin-protein ligase RNF113A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets